Astex – Oncology and CNS Drug Discovery & Development

Committed to the fight against cancer and CNS disorders

Committed to the fight against cancer and CNS disorders

World leading innovative drug discovery & development

Our research and development teams utilize our cutting edge technology platform in the relentless pursuit of innovative solutions that address the extensive and complex challenges in oncology and diseases of the CNS.

Astex has built a rich product portfolio with multiple drugs in clinical development

Latest from Astex

9 December 2019

Astex Pharmaceuticals presents topline data from the ASCERTAIN phase 3 study of its novel, oral hypomethylating agent cedazuridine and decitabine (ASTX727) in MDS and CMML at the American Society of Hematology Meeting in Orlando, FL.

3 September 2019

Astex Pharmaceuticals announces that its novel, oral hypomethylating agent ASTX727 has been granted orphan drug designation for the treatment of myelodysplastic syndromes (including chronic myelomonocytic leukemia) by the US FDA

7 June 2019

Taiho Oncology Announces Agreement with Otsuka to Commercialize Astex Pharmaceuticals’ Drug Candidates

Sustaining innovation

Innovative postdoctoral research fellowships

Learn more

Career Opportunities

We seek to attract and retain talented individuals who are passionate about improving patient outcomes.

Committed to the fight against cancer and CNS disorders